Emergent BioSolutions: The path to re-emergence
Emergent BioSolutions was arguably one batch away from being a pandemic hero.
Just months after COVID-19 gripped the world, the Maryland-based life sciences company had locked in deals to manufacture two of the five leading Operation Warp Speed vaccine candidates.
Shortly after Emergent had inked what eventually became a five-year deal worth at least $480 million with Johnson & Johnson to produce bulk drug substance for Janssen’s vaccine candidate, the U.S. government issued a $628 million task order to reserve capacity for a second OWS innovator — AstraZeneca. This resulted in Emergent signing an additional $261 million deal to make drug substances for the AstraZeneca-Oxford vaccine candidate.
Read the full article at: www.pharmamanufacturing.com
- About the Author
- Latest Posts
Over the past 11 years, Chris has grown BioBuzz into a respected brand that is recognized for its community building, networking events and news stories about the local biotech industry. In addition, he runs a Recruiting and Marketing Agency that helps companies attract top talent through a blended model that combines employer branding and marketing services together with a high powered recruiting solution.
